HIVMED Southern African Journal of HIV Medicine 1608-9693 2078-6751 AOSIS HIVMED-21-1107 10.4102/sajhivmed.v21i1.1107 Original Research Understanding adherence in virally suppressed and unsuppressed human immunodeficiency virus-positive urban patients on second-line antiretroviral treatment https://orcid.org/0000-0002-7870-1363 Gumede Siphamandla B. 1 2 https://orcid.org/0000-0002-4157-732X Venter Willem D.F. 1 https://orcid.org/0000-0003-3597-1643 Lalla-Edward Samanta T. 1 Ezintsha, a sub-division of Wits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa Department of Interdisciplinary Social Science, Public Health, Utrecht University, Utrecht, The Netherlands Corresponding author: Siphamandla Gumede, sgumede@cartafrica.org 11082020 2020 21 1 1107 24052020 13062020 © 2020. The Authors 2020 Licensee: AOSIS. This work is licensed under the Creative Commons Attribution License. Background

Understanding antiretroviral therapy (ART) adherence may assist in designing effective support interventions.

 Objectives

This study elicited perspectives on how to promote treatment adherence from virologically suppressed and unsuppressed patients receiving second-line ART.

 Methods

This was a cross-sectional study conducted with randomly selected patients active on second-line ART, from five public health facilities in the Johannesburg inner city. Data were collected on demographics, clinical information, participant’s experiences and ART knowledge. Virological failure was defined as exceeding 1000 copies/mL.

 Results

The study sample comprised 149 participants; of which 47.7% (n = 71) were virally unsuppressed and 69.1% (n = 103) were women; the median age of the participants was 42 years (interquartile range [IQR] 36–47 years). Experiencing medication-related difficulties in taking second-line ART (p = 0.003), finding second-line regimen more difficult to take than a first-line regimen (p = 0.001) and experiencing side effects (p < 0.001) were all subjective predictors of virological failure. Participants’ recommendations for improving adherence included the introduction of a single tablet regimen (31.6%, n = 55), reducing the dosage to once daily (26.4%, n = 46) and reducing the pill size for second-line regimen (4.0%, n = 7).

 Conclusion

The results of this study highlight the importance of improving patients’ knowledge about adherence and motivation to continue ART use despite the persistence of side effects and difficulties with taking medication.

 adherence viral load suppression virological failure antiretroviral therapy South Africa Introduction

The World Health Organization (WHO) defines adherence as the degree to which a patient is able to follow a treatment plan and take medication at prescribed times.1

Factors that affect treatment adherence include changes in daily routines, forgetting to take medication, side effects, depression, being away from home, comorbidity, lack of knowledge and desire to take treatment.2,3,4 In addition, patients experiencing financial constraints, social issues such as the fear of disclosure and lack of understanding of treatment benefits are more prone to non-adherence to treatment and illnesses.5,6 Some studies have reported disclosure and relationship with the person being disclosed to as predictors of adherence.7,8

The South African government’s adherence promotion strategies include routine viral load monitoring, adherence counselling, pill counting, adherence clubs and routine completion of clinical stationery.9,10,11 Despite all these antiretroviral therapy (ART) adherence strategies being implemented, treatment failure amongst patients on first- and second-line ART remains an issue.12 Lapses in ART medication adherence can lead to viral rebound with ongoing immunosuppression and viral resistance.1,13,14 However, not much is understood about the perspectives of patients regarding adherence challenges.15,16

Therefore, this study sought to describe and obtain perspectives on treatment adherence from two separate groups of patients on second-line therapy, those who were suppressed and those who were not, to understand treatment-taking behaviour.

 Materials and methods Study design and setting

This was a cross-sectional study conducted between July and August 2018 in a sub-population of patients receiving second-line ART at the end of June 2018. Five public health facilities in inner-city Johannesburg (two hospitals, one community health centre and two primary healthcare clinics) were included in the study.

 Study population

The study population comprised patients aged 18 years and older who were on second-line ART for at least 1 month or longer.

 Data collection Sample selection and recruitment

We randomly sampled 10% of the population of 1500 eligible patients. The total number of active patients on second-line treatment per facility was divided by the total sample size (n = 150) to determine the interval that needed to be used to select the eligible patients. Using this formula, every nth (different for each facility) record from the register or list of active patients on second-line treatment in each facility was selected and recruited to the study until the facility sample size was reached. Once the eligible patients were identified, they were invited to participate in the study in one of the two ways: telephonically or in facility recruitment where researchers met them at the facility during their scheduled clinic visit. For the patients who refused to participate in the study, the next nth patient was recruited.

 Data collection, tool and variables

A pretested semi-structured questionnaire was used, which consisted of five sections: (1) demographic data, (2) comorbidity information, (3) human immunodeficiency virus (HIV) diagnosis and care information, (4) experiences on the first-line regimen and adherence and (5) experiences on second-line regimen and adherence. Information collected included demographic information (facility name, sex, age, relationship status, employment status and education level), comorbidity information, experiences on both first- and second-line treatment, disclosure information, duration on ART, reasons for starting ART, side effects, self-reported treatment interruptions, challenges with taking second-line treatment, treatment supporter information and insights into how adherence could be improved.

 Questionnaire administration

Data were collected by the principal investigator and a trained research assistant. The interviews were conducted in English as it was the most commonly spoken language in the study setting and all participants could speak it.

 Data entry, cleaning and analysis

Data were captured into REDCap immediately after interviews were conducted. The research team conducted data clean-up by running data quality checks in REDCap and STATA (quantitative data). For the closed-ended questions, we assessed the association between outcome variables and selected socio-demographic and health-related characteristics. Pearson’s chi-squared test was used to assess trend associations between categorical variables. Continuous data were summarised and analysed using the median and interquartile ranges (IQRs). Logistic and multiple logistic regression models (bivariate and multivariate logistic regression) were built for key outcome variables, such as viral load, difficulties in taking second-line regimen and side effects, to identify independent predictors. We reported unadjusted and adjusted odds ratios (ORs), 95% confidence interval (CI) and p-values – p-values that were less than 0.05 were considered significant. Open-ended questions were analysed using qualitative data analysis methods. Data were coded and thematic analysis was performed. Where appropriate, quotations have been included to support the reported results.

 Ethical consideration

Ethical approval to conduct the study was obtained from the University of the Witwatersrand Human Research Ethics Committee (ethical clearance number: M170691). Approval was also granted by the Johannesburg Health District (DRC Ref No. 2017-08-003 and NHRD Ref No. GP_201708_030). Participants were informed that participation in the study was voluntary and that refusal would not affect their relationship with their healthcare provider or facility. All patients who agreed to participate in the study signed an informed consent form. To ensure confidentiality, there were no linkages between the data collected in the questionnaire and the patients’ clinic information. Participants were reimbursed for their travel.

 Results Sample characteristics

A total of 150 out of 1500 active patients on second-line ART across the five public health facilities were interviewed (69.1%, n = 103 women). During the quality checking processes, we found that one of the participants was younger than 18 years and was subsequently omitted from the analysis. The median age of the participants was 42 years (IQR 36–47 years). Most of the participants were single (38.1%, n = 57); 30.2% (n = 45) participants were married. Nearly two-thirds of the participants were born in South Africa (61.1%, n = 91), whilst almost one-third of the participants were born in Zimbabwe (32.9%, n = 49). The majority (87.2%, n = 130) of participants had completed at least their secondary or high school-level education. A minority (8.1%, n = 12) of participants had completed tertiary qualifications; 4.7% (n = 7) participants had never attended a school. Of the total participants, 45.6% (n = 68) were unemployed. The majority of participants were identified as Christian (87.9%, n = 131). Hypertension (65.1%, n = 28/43), diabetes (9.3%, n = 4/43) and hypercholesterolaemia (9.3%, n = 4/43) were the most common concomitant conditions reported by the participants. The average distance travelled to reach a health facility was 5 km (IQR: 2 km – 15 km), with 57.7% (n = 86) participants travelling 5 km or less to reach the health facility.

 Socio-demographic and virological status

Table 1 shows the socio-demographic characteristics disaggregated by virological status. Nearly half (47.7%, n = 71) of the participants interviewed had virological failure (VLF), with women accounting for 73.2% (n = 52). With regard to age, of the total unsuppressed participants, 39.4% (n = 28) were between 30 and 39 years. Of the participants with virological suppression (VLS), 29.5% (n = 23) had comorbidity compared to VLF participants (28.2%, n = 20).

Socio-demographic and treatment-taking characteristics disaggregated by virological status of second-line participants in five health facilities in the Johannesburg inner city.

Variable Total patient or participants recruited Total N = 149 (100)
 Virological status
 p
Suppressed (VLS), 78 (52.3)
 Unsuppressed (VLF), 71 (47.7)
n % n % n %
Facility 0.001*
Charlotte Maxeke Johannesburg Academic Hospital 32 21.5 19 24.4 13 18.3
Hillbrow Community Health Centre 86 57.7 43 55.1 43 60.6
South Rand Hospital 21 14.1 16 20.5 5 7.0
Primary Healthcare Clinics (Malvern Clinic Yeoville Clinic†) 10 6.7 0 0.0 10 14.1
Sex 0.300
Female 103 69.1 51 65.4 52 73.2
Male 46 30.9 27 34.6 19 26.8
Age, Median (42, IQR: 35–47) (years) 0.152
< 30 11 7.4 3 3.9 8 11.3
30–39 52 34.9 24 30.8 28 39.4
40–45 43 28.9 25 32.1 18 25.4
45+ 43 28.9 26 33.3 17 23.9
Country of birth 0.085
South Africa 91 61.1 42 53.9 49 69.0
Zimbabwe 49 32.9 32 41.0 17 23.9
Other 9 6.0 4 5.1 5 7.0
Home language 0.893
Zulu 62 41.6 32 41.0 30 42.3
Ndebele 36 24.2 21 26.9 15 21.1
Xhosa 12 8.1 6 7.7 6 8.5
Sotho 12 8.1 5 6.4 7 9.9
Other 27 18.1 14 18.0 13 18.3
Relationship status 0.310
Married 45 30.2 28 35.9 17 23.9
Cohabiting 38 25.5 16 20.5 22 31.0
Single 57 38.3 30 38.5 27 38.0
Other 9 6.0 4 5.1 5 7.0
Highest education level completed 0.737
Never went to school 7 4.7 4 5.1 3 4.2
Secondary or high school 130 87.2 69 88.5 61 85.9
Tertiary 12 8.1 5 6.4 7 9.9
Employment status 0.613
Employed 65 43.6 37 47.4 28 39.4
Unemployed 68 45.6 33 42.3 35 49.3
Other‡ 16 10.7 8 10.3 8 11.3
Religion 0.098
Christian 131 87.9 67 85.9 64 90.1
Ancestral/traditional 8 5.4 7 9.0 1 1.4
Other 10 6.7 4 5.1 6 8.5
Comorbidity 0.859
Yes 43 28.9 23 29.5 20 28.2
No 106 71.1 55 70.5 51 71.8
Distance travelled to the facility, 0.764
Median (5, IQR: 2–15)
5 km or less 86 57.7 45 57.7 41 57.8
6 km – 10 km 21 14.1 12 15.4 9 12.7
11 km – 20 km 23 15.4 10 12.8 13 18.3
Above 20 km 19 12.8 11 14.1 8 11.3
Who was the first person to whom you disclosed your HIV status? 0.228
Partner 70 47.0 33 42.3 37 52.1
Family or relative member 77 51.7 43 55.1 34 47.9
Friend 2 1.3 2 2.6 0 0.0
How long did it take you to disclose your HIV status? 0.306
1 week 94 63.1 48 61.5 46 64.8
1–2 weeks 8 5.4 4 5.1 4 5.6
3–4 weeks 4 2.7 4 5.1 0 0.0
More than 4 weeks 42 28.2 22 28.2 20 28.2
Never disclosed 1 0.7 0 0.0 1 1.4
Do you have anyone supporting you in taking your ARVs currently? 0.755
Yes 118 79.2 61 78.2 57 80.3
No 31 20.8 17 21.8 14 19.7
Do you feel the current regimen is difficult to take compared to the previous regimen(s)? 0.001*
Yes 78 52.3 31 39.7 47 66.2
No 71 47.7 47 60.3 24 33.8
Have you been experiencing difficulties in taking the current regimen? 0.003*
Yes 57 38.3 21 26.9 36 50.7
No 92 61.7 57 73.1 35 49.3
Have you experienced any side effects since you switched regimens or drugs? < 0.001*
Yes 71 47.7 26 33.3 45 63.4
No 78 52.3 52 66.7 26 36.6
Have you ever stopped taking the current regimen for over a month? 0.728
Yes 5 3.4 3 3.8 2 2.8
No 144 96.6 75 96.2 69 97.2
Have you ever felt like stopping the current regimen or drugs completely? 0.642
Yes 15 10.1 7 9.0 8 11.3
No 134 89.9 71 91.0 63 88.7
Have you ever felt like switching current regimen or drugs for something else? 0.142
Yes 58 38.9 26 33.3 32 45.1
No 91 61.1 52 66.7 39 54.9

N, number; VLS, virological suppression; n, number; VLF, virological failure; p, probability value; IQR, interquartile range; km, kilometre; ARVs, antiretrovirals; HIV, human immunodeficiency virus.

, Second-line patients are often managed at a higher level of facility.

, People not looking for employment at that time, for example, students and housewives.

, p < 0.05.

 Disclosure, treatment support and virological status

Almost all the participants’ first disclosure of their HIV status was to a partner or relative (98.7%, n = 147 combined). More VLS participants (55.1%, n = 43) disclosed about their HIV status to a family member first, whilst most VLF participants (52.1%, n = 37) chose to disclose to their partners first. Almost no disclosure to friends was reported. Disclosure did not show any statistical significance. Participants typically (63.1%, n = 94) disclosed within 1 week after HIV diagnoses, with more VLF participants reporting early disclosure than VLS participants (64.8%, n = 46 vs. 61.5%, n = 48). Most participants (79.2%, n = 118) had treatment supporters (VLF = 80.3%, n = 57; VLS = 78.2%, n = 61). Whilst 10.1% (n = 15) of participants felt like stopping treatment completely at some point, only 3.4% (n = 5) stopped treatment for longer than 1 month, more in VLS participants, although this was not statistically significant.

 Factors of virological failure and adherence

Overall, there were more participants (52.3%, n = 78) who felt that taking a second-line regimen was difficult compared to the first-line regimen, with the VLF group (66.2%, n = 47, p = 0.001) predominantly reporting this challenge. Generally, 38.3% (n = 57/149) experienced difficulties in taking the second-line regimen (p = 0.003). Of these, about two-thirds (63.2%, n = 36) were VLF participants (p = 0.003). Just under half (47.7%, n = 71/149) of the participants experienced side effects whilst taking their second-line regimen, and of these, 63.4% (n = 45) were VLF participants (p < 0.001).

Table 2 presents results from both bivariate and multivariate logistic regression analysis. No association was detected between VLF and relationship status in bivariate analysis. However, in multivariate analysis, participants who cohabit were three times more likely to have a VLF than those who are married (adjusted odds ratios [AORs] 3.1, 95% CI = 1.1–8.9; p = 0.035). Unemployed participants were two and a half times more likely to have treatment-related side effects compared to employed participants (AOR 2.5, 95% CI = 1.1–5.7; p = 0.023). Results for age did not show any statistical significance but older people were less likely to be unsuppressed.

Logistic regression analysis between outcome variables and socio-demographic characteristics of second-line participants in Johannesburg inner city.

Variable Virological failure
 Experiencing difficulties taking second-line regimen
 Feeling that second-line regimen is difficult to take
 Side effects
UOR p AOR p UOR p AOR p UOR p AOR p UOR p AOR p
Facility
CMJAH Ref - Ref - Ref - Ref - Ref - Ref - Ref - Ref -
HCHC 1.3 (0.6–3.1) 0.460 1.6 (0.6–4.4) 0.475 2.0 (0.8–4.7) 0.113 2.0 (0.7–5.7) 0.185 2.4 (1.1–5.6) 0.037* 1.7 (0.7–4.8) 0.246 2.1 (0.9–4.8) 0.080 1.8 (0.7–4.9) 0.233
SRH 0.4 (0.1–1.4) 0.168 0.4 (0.1–1.4) 0.136 0.3 (0.1–1.5) 0.170 0.4 (0.1–2.1) 0.301 0.7 (0.2–2.2) 0.503 0.6 (0.2–2.4) 0.505 0.7 (0.2–2.2) 0.503 0.5 (0.1–1.8) 0.266
PHC (Yeoville and Malvern) 1 - 1 - 0.9 (0.2–4.4) 0.941 0.7 (0.1–3.8) 0.631 15.0 (1.7–133.6) 0.015* 8.6 (0.8–87.7) 0.069 1.7 (0.4–7.0) 0.484 1.7 (0.3–8.8) 0.538
Age (years)
< 30 Ref - Ref - Ref - Ref - Ref - Ref - Ref - Ref -
30–39 0.4 (0.1–1.8) 0.259 0.6 (0.1–2.9) 0.496 0.7 (0.2–2.6) 0.614 0.8 (.2–3.1) 0.717 1.2 (0.3–4.6) 0.815 1.6 (0.3–7.6) 0.551 1.0 (0.3–3.6) 0.966 1.2 (0.3–5.0) 0.786
40–45 0.3 (0.06–1.2) 0.079 0.5 (0.1–2.9) 0.462 0.5 (0.1–1.9) 0.301 0.8 (.2–3.3) 0.717 0.5 (0.1–1.8) 0.256 0.6 (0.1–3.2) 0.597 0.8 (0.2–3.0) 0.736 1.7 (0.4–7.4) 0.486
45+ 0.2 (0.06–1.1) 0.059 0.6 (0.1–3.4) 0.595 0.3 (0.1–1.1) 0.074 0.5 (0.1–2.1) 0.327 0.4 (0.1–1.5) 0.160 0.7 (0.1–3.3) 0.612 0.5 (0.1–1.9) 0.301 0.9 (0.2–4.3) 0.935
Gender
Female Ref - Ref - Ref - Ref - Ref - Ref - Ref - Ref -
Male 0.7 (0.3–1.4) 0.301 0.9 (0.4–2.1) 0.776 0.6 (0.3–1.3) 0.191 0.5 (0.2–1.2) 0.139 0.5 (0.3–1.1) 0.073 0.6 (0.3–1.3) 0.244 0.7 (0.3–1.4) 0.301 0.9 (0.4–2.1) 0.857
Relationship status
Married Ref - Ref - Ref - Ref - Ref - Ref - Ref - Ref -
Single 1.5 (0.7–3.3) 0.332 2.1 (0.8–5.4) 0.136 1.5 (0.7–3.4) 0.336 1.3 (0.5–3.2) 0.598 1.1 (0.5–2.5) 0.777 0.9 (0.4–2.2) 0.799 2.0 (0.9–4.5) 0.087 2.0 (0.8–4.8) 0.143
Cohabiting 2.3 (0.9–5.5) 0.069 3.1 (1.1–8.9) 0.035* 1.6 (0.7–4.0) 0.300 1.2 (.4–3.2) 0.751 1.0 (0.4–2.3) 0.949 0.7 (0.2–1.9) 0.470 2.0 (0.8–4.9) 0.120 2.2 (0.8–5.9) 0.134
Other 2.1 (0.5–8.7) 0.328 2.4 (0.5–13.1) 0.301 1.8 (0.4–7.6) 0.442 2.9 (0.5–16.3) 0.238 0.3 (0.05–1.3) 0.105 0.3 (0.04–1.8) 0.170 2.3 (0.5–9.7) 0.269 2.7 (0.5–14.2) 0.239
Highest education level completed
Secondary/High school Ref - Ref - Ref - Ref - Ref - Ref - Ref - Ref -
Tertiary 1.6 (0.5–5.3) 0.452 2.2 (0.5–9.3) 0.279 1.1 (0.3–3.8) 0.827 0.9 (0.2–3.6) 0.897 0.6 (0.2–2.0 0.422 0.8 (0.2–3.3) 0.764 1.1 (0.3–3.7) 0.838 1.1 (0.3–4.1) 0.943
Never went to school 0.9 (0.2–3.9) 0.834 0.4 (0.1–3.3) 0.421 0.6 (0.1–3.4) 0.602 0.8 (0.1–5.3) 0.854 0.6 (0.1–3.0) 0.573 0.4 (0.06–2.4) 0.309 1.5 (0.3–7.0) 0.600 0.9 (0.2–5.1) 0.935
Employment status
Employed Ref - Ref - Ref - Ref - Ref - Ref - Ref - Ref -
Unemployed 1.4 (0.7–2.8) 0.333 1.5 (0.7–3.5) 0.304 0.9 (0.4–1.8) 0.705 0.8 (0.4–1.9) 0.698 1.2 (0.6–2.4) 0.550 1.5 (0.7–3.5) 0.314 2.2 (1.1–4.3) 0.030* 2.5 (1.1–5.7) 0.023*
Other 1.3 (0.4–4.0) 0.618 0.8 (0.2–3.5) 0.798 1.6 (0.5–4.8) 0.402 2.0 (0.6–7.1) 0.289 1.3 (0.4–4.0) 0.616 1.4 (0.4–5.1) 0.620 1.2 (0.4–3.8) 0.699 1.3 (0.4–4.7) 0.649
Distance travelled to the facility
5 km or less Ref - Ref - Ref - Ref - Ref - Ref - Ref - Ref -
6 km – 10 km 0.8 (0.3–2.2) 0692 1.0 (0.3–3.0) 0.959 0.7 (0.2–1.8) 0.420 0.8 (0.3–2.3) 0.639 0.8 (0.3–2.0) 0.565 1.1 (0.4–3.2) 0.916 0.9 (0.3–2.3) 0.771 0.9 (0.3–2.6) 0.828
11 km – 20 km 1.4 (0.6–3.6) 0.452 2.5 (0.8–7.6) 0.117 0.5 (0.2–1.3) 0.145 0.6 (0.2–1.8) 0.347 0.3 (0.1–0.8) 0.017* 0.5 (0.2–1.5) 0.200 0.7 (0.3–1.9) 0.513 0.8 (0.3–2.3) 0.662
Above 20 km 0.8 (0.3–2.2) 0.660 1.2 (0.4–3.8) 0.790 1.0 (0.4–3.0) 0.957 1.4 (0.4–4.7) 0.613 0.6 (0.2–1.7) 0.344 0.9 (0.3–2.7) 0.787 0.6 (0.2–1.5) 0.262 0.6 (0.2–1.9) 0.363

Note: All logistic regression analyses were performed at 95% CI.

UOR, unadjusted odds ratios; AOR, adjusted odds ratios; p, probability value; CMJAH, Charlotte Maxeke Johannesburg Academic Hospital; HCHC, Hillbrow Community Health Centre; SRH, South Rand Hospital; PHC, primary healthcare clinic; Ref, reference; km, kilometre; CI, confidence interval.

, p < 0.05.

 Treatment-taking behaviour

Table 3 presents the reported treatment behaviour of the participants for the duration of receiving ART. There were more reports of treatment interruption whilst participants were on first-line treatment (n = 52). With respect to the reported treatment interruption whilst on second-line regimen, there was no distinct difference between the failing (n = 8) and suppressed (n = 5) groups. Both groups equally relied on themselves to remember to take their treatment (‘naturally [I] remember taking my pills [VLF, woman, 31 years]; [I am] experienced on remembering my time’ [VLS, man, 41 years]). Some of the reasons for interrupting treatment included stopping to take tuberculosis medication (‘yes, interruption due to TB recurrence’ [VLF, woman, 22 years]) and no medication availability whilst relocating (‘I once interrupted my treatment due to the shortage of drugs as I relocated in South Africa and I did not have a proper transfer letter’ [VLF, man, 38 years]). In the group with no reported second-line treatment interruption, more virologically suppressed participants (n = 21) listed using an alarm as a reminder. Several participants used the timeslots of popular local television programmes or the news (n = 14) as reminders to take their medication.

History of antiretroviral treatment-taking behaviour.

Variable First-line treatment
 Second-line treatment
Treatment interruption
 No treatment interruption
 Did not report on treatment interruption
 Treatment interruption
 No treatment interruption
 Did not report on treatment interruption
VLS VLF VLS VLF VLS VLF
52 91 6 5 8 67 56 6 7
Medication alert
Alarm 21 53 2 1 2 21 13 2 1
TV 5 9 - 1 1 3 1 - -
Memory 14 14 2 1 4 30 30 3 4
Family 7 9 1 1 - 2 4 - -
Did not report 5 6 1 1 1 11 8 1 2
Daily frequency
Once 16 37 1 - 2 5 1 1 1
Twice 33 52 4 5 6 60 55 5 5
Did not report 3 2 1 - - 2 - - 1
Storage
Cupboard 31 57 3 4 7 39 35 3 5
Handbag 14 22 1 - - 18 17 1 1
Cooler bag or fridge 1 1 1 - - - 1 1 -
Pill box 3 7 - - - 8 3 - -
Other 1 1 - - 1 - - 1 -
Did not report 2 3 1 1 - 2 - - 1

ART, antiretroviral treatment; VL, viral load; VLS, viral load suppression; VLF, viral load failure; TV, television.

Table 4 presents the bivariate and multivariate logistic regression analyses for ART-taking behaviour. There was no association between participants’ treatment-taking behaviour (i.e. medication alert, daily frequencies and pill storage) and VLF. However, participants who relied on their memory as a reminder to take medication (whilst on first-line regimen) were almost three times more likely to interrupt their first-line treatment than those who relied on an alarm (AOR: 2.6, 95% CI = 1.0–6.4, p = 0.042). There was no association found between medication alert or frequency of taking medication and second-line treatment interruption. Participants who used their handbag to store their medication were the least likely to experience second-line treatment interruption (OR: 0.2, 95% CI = 0.05–1.0, p = 0.054).

Logistic regression analysis between virological failure, regimens (first-line and second-line regimen) and treatment-taking behaviour indicators in health facilities in Johannesburg inner city.

Variable Virological failure
 First-line interruption
 Second-line interruption
UOR p AOR p UOR p AOR p UOR p AOR p
Medication alert
Alarm 1 - 1 - 1 - 1 - 1 - 1 -
TV 0.8 (0.1–4.6) 0.756 0.8 (0.1–5.5) 0.837 1.3 (0.4–4.4) 0.634 1.7 (0.5–5.7) 0.429 2.8 (0.4–19.1) 0.284 2.1 (0.2–18.2) 0.497
Memory 1.7 (0.8–3.7) 0.196 1.7 (0.8–3.8) 0.194 2.8 (1.2–6.6) 0.023* 2.6 (1.0–6.4) 0.042* 1.1 (0.4–3.3) 0.818 1.1 (0.3–3.7) 0.859
Family 1.9 (0.4–8.1) 0.398 2.1 (0.5–9.8) 0.339 2.7 (0.9–7.9) 0.069 2.7 (0.9–8.4) 0.080 0.7 (0.07–6.7) 0.764 0.5 (0.08–6.5) 0.592
Did not report 1.3 (0.4–3.6) 0.677 1.2 (0.4–3.6) 0.694 2.1 (0.6–6.8) 0.236 1.6 (0.5–5.8) 0.447 1.3 (0.3–5.0) 0.745 1.5 (0.3–6.9) 0.585
Daily frequency
Once 1 - 1 - 1 - 1 - 1 - 1 -
Twice 1.4 (0.4–5.2) 0.604 1.6 (0.4–6.4) 0.479 1.7 (0.8–3.5) 0.153 1.7 (0.8–3.7) 0.162 0.3 (0.07–1.1) 0.060 0.3 (0.08–1.5) 0.149
Did not report 0.8 (0.05–11.3) 0.835 0.8 (0.05–13.3) 0.883 4.6 (0.8–27.9) 0.095 3.7 (0.6–26.1) 0.177 Empty - Empty -
Storage
Cupboard 1 - 1 1 - 1 - 1 - 1 -
Handbag 1.0 (0.5–2.2) 1.000 1.0 (0.4–2.2) 0.964 1.1 (0.5–2.5) 0.782 1.4 (0.6–3.1) 0.478 0.2 (0.05–1.0) 0.054 0.2 (0.05–1.0) 0.055
Cooler bag or fridge 0.5 (0.04–5.7) 0.577 0.5 (0.04–6.2) 0.592 3.5 (0.3–40.3) 0.312 3.8 (0.3–50.5) 0.309 1.9 (0.2–22.3) 0.602 1.9 (0.1–27.4) 0.606
Pill box 0.4 (0.09–1.5) 0.166 0.3 (0.08–1.4) 0.131 0.9 (0.2–3.7) 0.816 1.2 (0.3–5.5) 0.809 Empty - Empty -
Other Empty - Empty - 3.5 (0.3–40.3) 0.312 1.7 (0.1–22.8) 0.678 Empty - Empty -
Did not report 1.0 (0.2–5.2) 1.000 1.1 (0.2–6.3) 0.931 2.3 (0.5–11.1) 0.284 2.3 (0.4–12.2) 0.336 1.9 (0.3–11.3) 0.470 2.3 (0.3–16.9) 0.430

Note: All logistic regression analyses were performed at 95% CI.

UOR, unadjusted odds ratios; AOR, adjusted odds ratios; p, probability value; Ref, reference; CI, confidence interval.

, p < 0.05.

 Recommendations from participants

The study participants made 175 recommendations for improving adherence (see Table 5). Coformulation in single tablets, only needing to take one dose of medication daily (preferably at night) and education about being adherent were listed as the most effective mechanisms to improve adherence on second-line treatment. Some examples of recommendations from participants include the following:

‘Education should be emphasised through adherence classes. Reinforce on the benefits of ART’. (VLS, female, 38 years old)

‘Availing a single-dose treatment for the second-line patients would enable them to adhere to treatment. Further ongoing education would also help’. (VLF, female, 39 years old)

Participants’ perspectives on how adherence can be improved amongst second-line patients.

Recommendation Number of people citing the recommendation
Coformulation in single tablets 55
One dose 46
Education 24
No recommendations 12
Injection 9
Psychosocial support 9
Smaller pills 7
No side effects 4
Clinic operating times 2
Counselling 1
Decreased frequency of treatment ingestion 1
Follow-up 1
Liquid 1
More research needed 1
SMS reminders 1
Trust patients 1
TOTAL 175

SMS, short message service.

Other recommendations included the development of injectable ART (n = 9, seven women and two men) and the provision of psychosocial support (particularly related to poverty and ensuring food supply):

‘Should consider addressing the psychosocial needs of patients on second line as they have to adhere to treatment but sometimes they do not have enough food to eat’. (VLF, female, 45 years old)

Single recommendations to improve adherence included treatment reminders (n = 1), additional counselling (n = 1) and minimising the number of times second-line regimen is taken per day (n = 1). One patient felt that healthcare workers trusting that their patients took their medication as prescribed would promote treatment adherence. Lastly, 12 participants did not have any recommendations (mainly because of not experiencing any pill-taking challenges), as shown in the following statement:

‘The current regimen is fine with me, therefore, I will suggest no change’. (VLS, male, 41 years old)

 Discussion

This study sought to describe and understand treatment adherence and possible treatment support interventions from patients receiving second-line ART.

It has been reported that relationship dynamics influence ART adherence and VLS in that being married or having a committed and supportive partner tended to foster an environment for better clinical outcomes in HIV-positive people.17,18 Studies from South Africa and the United Kingdom found that HIV-positive married individuals had better clinical outcomes compared to any other relationship status.19,20 Similarly, our study found that single and unmarried people living with their partners were more likely to be virally unsuppressed.

Not statistically significant but important for consideration in adherence strengthening, our study showed that being younger was a predictor of VLF, which was congruent with previous studies.21,22,23 We noted VLS in those participants who resided further away from the health facilities. This is not in agreement with findings of studies conducted in Uganda, Ghana and Burkina Faso,24,25,26 which reported that individuals who resided closer to a health facility were more likely to seek healthcare.

Late disclosure may hinder adherence or treatment support and subsequently yield poor clinical outcomes.27 Whilst the majority of participants (63%) disclosed their HIV status 1 week after diagnoses, about 28% took longer than 4 weeks to disclose. Early disclosure, particularly to a family member or partner, has been strongly associated with improved adherence.8,28,29 Disclosure to a family member or partner has been linked with adequate psychosocial support which in turn facilitates adherence to treatment.8,29,30,31,32 However, the findings of our study suggest that disclosure and dependence on a treatment supporter are likely not to produce desired adherence levels (and did not feature in the list of participant recommendations), indicating that disclosure and treatment support should be assessed in combination with other adherence strategies instead of as a single consideration or mechanism.33

Unsurprisingly, the more toxic the second-line multi-pill, and regimens requiring medication to be taken multiple times a day, were seen as significantly harder to take than a single tablet daily well-tolerated first-line regimen. These views were consistent with reports from other studies that attributed similar challenges to taking second-line regimen.34,35,36

Participants who did not interrupt ART mainly reported using an alarm as a reminder for taking their medication. This finding suggests the need to explore external reminder mechanisms for improving adherence in this setting, considering that about 15% of VLF participants reported not using any external reminders. Various studies have also found a trend towards better adherence amongst patients who used external reminders.37,38,39 In addition, our study showed that participants who used their handbags to store their medication were more likely to adhere to treatment. This finding is in line with other studies that have reported having a handbag to have pills all the time as the preferred ART storage by patients.40,41,42

Side effects are an important predictor of poor adherence, and cumulative toxicity associated with ART, especially in second-line regimens.43,44,45 We found that participants with VLF were more likely to have treatment-related side effects. Furthermore, those participants with side effects were more likely to be unemployed. Although this was not explored further in our study, various studies have reported that employed patients can manage their health and side effects better than their unemployed counterparts.46,47,48

Participants had ideas regarding drug formulation that may improve adherence. These included a fixed-dose combination, a dosage taken once a day and reducing the pill size. Furthermore, the participants suggested that education on the benefits of taking ART could improve adherence, whilst a few participants also suggested the implementation of injectable ART. Various studies have recommended similar strategies,49,50,51 with the effectiveness of some of these strategies being previously reported for first-line regimens.51,52

Study limitations and strengths

This study had several limitations. Firstly, the study relied on participants’ self-reports, prompting a likelihood that socially desirable answers may have been provided. However, to control for this, information such as viral load, side effects and comorbidity was verified by checking participants’ medical records as part of data quality checks for the study. Secondly, the clinical measure for adherence considered viral load only. Finally, the sample might be small for the results to be generalised to all patients receiving second-line ART. However, the direction and size of effect were generally consistent, suggesting that the study findings may be robust despite these limitations.

 Conclusion

Participants on a second-line antiretroviral regimen had firm recommendations regarding improving adherence, largely focused on administration, reduced dosing and pill burden. The study results suggest the importance of improving patients’ knowledge about treatment and adherence and motivation to continue ART use despite the persistence of side effects. Drug manufacturers and health programmers must consider such recommendations as they modify and implement new ART regimens and programmes. Lastly, treatment support interventions recommended in this study need to be tested in practice to determine their efficacy for large-scale implementation.

 Acknowledgements

The authors would like to thank all the facilities and relevant health and research authorities from the City of Johannesburg for allowing the research team to engage in a partnership to strengthen health service delivery through technical assistance and research. They also thank the participants for sharing their experiences, views and recommendations, and Jean Claude Nkembi for his assistance with data collection and capture.

Competing interests

The authors declare that they have no competing interests.

 Authors’ contributions

S.B.G. and S.T.L.-E. designed the study and supervised the data extraction at the facilities. S.B.G. analysed the quantitative data and S.T.L.-E. analysed the qualitative data. S.B.G. interpreted the data and prepared the first draft of the manuscript, which was revised by S.T.L.-E. and W.D.F.V. All authors read and approved the final manuscript.

 Funding information

This study was funded through the OPTIMIZE project. OPTIMIZE (AID-OAA-A-15-00069) is funded by the United States Agency for International Development (USAID) under the US President’s Emergency Plan for AIDS Relief (PEPFAR). S.B.G. was supported by the Consortium for Advanced Research Training in Africa (CARTA). It is jointly led by the African Population and Health Research Center and the University of the Witwatersrand and funded by the Carnegie Corporation of New York (Grant No. B 8606.R02), Swedish International Development Cooperation Agency (SIDA) (Grant No. 54100113), the Developing Excellence in Leadership, Training and Science (DELTAS) Africa Initiative (Grant No. 107768/Z/15/Z) and Deutscher Akademischer Austauschdienst (DAAD). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences’ (AAS) Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa’s Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (the United Kingdom [UK]) and the UK government.

 Data availability statement

The data sets used or analysed in this study are available from the corresponding author upon reasonable request.

 Disclaimer

The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of any affiliated agency of the authors.

 References World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach [homepage on the Internet]. WHO Guidelines. 2013 [cited 2019 Aug 14]. Available from: https://apps.who.int/iris/bitstream/handle/10665/85321/9789241505727_eng.pdf?sequence=1 Fox MP, Berhanu R, Steegen K, et al. Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in Johannesburg, South Africa. Trop Med Int Heal. 2016;21(9):1131–1137. https://doi.org/10.1111/tmi.12741 Nieuwlaat R, Wilczynski N, Navarro T, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014;11:1–538. https://doi.org/10.1002/14651858.CD000011.pub4 World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV [homepage on the Internet]. World Health Organization; 2015 [cited 2019 Aug 14]. Available from: https://apps.who.int/iris/bitstream/handle/10665/186275/9789241509565_eng.pdf?sequence=1 Goudge J, Ngoma B. Exploring antiretroviral treatment adherence in an urban setting in South Africa. J Public Health Policy. 2011;32:S52–S64. https://doi.org/10.1057/jphp.2011.22 Elliott JH, Lynen L, Calmy A, et al. Rational use of antiretroviral therapy in low-income and middle-income countries: Optimizing regimen sequencing and switching. AIDS. 2008;22(16):2053–2067. https://doi.org/10.1097/QAD.0b013e328309520d Gross R, Zheng L, Rosa A La, et al. Partner-based adherence intervention for second-line antiretroviral therapy (ACTG A5234): A multinational randomised trial. Lancet HIV. 2(1):e12–19. https://doi.org/10.1016/S2352-3018(14)00007-1 Onoya D, Nattey C, Budgell E, et al. Predicting the need for third-line antiretroviral therapy by identifying patients at high risk for failing second-line antiretroviral therapy in South Africa. AIDS Patient Care STDS. 31(5):205–212. https://doi.org/10.1089/apc.2016.0291 Gill CJ, Hamer DH, Simon JL, Thea DM, Sabin LL. No room for complacency about adherence to antiretroviral therapy in sub-Saharan Africa. AIDS. 2005;19(12):1243–1249. https://doi.org/10.1097/01.aids.0000180094.04652.3b South African National Department of Health. National consolidated guidelines for the prevention of mother-to-child transmission of HIV (PMTCT) and the management of HIV in children, adolescents and adults [homepage on the Internet]. Health Policy. 2015 [cited 2019 Aug 20]. Available from: https://sahivsoc.org/Files/ARTGuidelines15052015.pdf Nnambalirwa M, Govathson C, Evans D, McNamara L, Maskew M, Nyasulu P. Markers of poor adherence among adults with HIV attending Themba Lethu HIV Clinic, Helen Joseph Hospital, Johannesburg, South Africa. Trans R Soc Trop Med Hyg. 2016;110(12):696–704. https://doi.org/10.1093/trstmh/trx003 World Health Organization. HIV drug resistance report 2017 [homepage on the Internet]. World Health Organization; 2017 [cited 2019 Aug 20]. Available from: https://apps.who.int/iris/bitstream/handle/10665/255896/9789241512831-eng.pdf?sequence=1 Hertogs K, Bloor S, De Vroey V, et al. A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V. Antimicrob Agents Chemother. 2000; 44(3):568–573. https://doi.org/10.1128/AAC.44.3.568-573.2000 Achappa B, Madi D, Bhaskaran U, Ramapuram JT, Rao S, Mahalingam S. Adherence to antiretroviral therapy among people living with HIV. N Am J Med Sci. 2013;5(3):220–223. https://doi.org/10.4103/1947-2714.109196 Pagès-Puigdemont N, Mangues MA, Masip M, et al. Patients’ perspective of medication adherence in chronic conditions: A qualitative study. Adv Ther. 2016; 33:1740–1754. https://doi.org/10.1007/s12325-016-0394-6 Laba TL, Lehnbom E, Brien J-A, Jan S. Understanding if, how and why non-adherent decisions are made in an Australian community sample: A key to sustaining medication adherence in chronic disease? Res Social Adm Pharm. 2015;11(2):154–162. https://doi.org/10.1016/j.sapharm.2014.06.006 Conroy A, Leddy A, Johnson M, Ngubane T, Van Rooyen H, Darbes L. ‘I told her this is your life’: Relationship dynamics, partner support and adherence to antiretroviral therapy among South African couples. Cult Heal Sex. 2017;19(11):1239–1253. https://doi.org/10.1080/13691058.2017.1309460 Johnson MO, Dilworth SE, Taylor JM, Darbes LA, Comfort ML, Neilands TB. Primary relationships, HIV treatment adherence, and virologic control. AIDS Behav. 2012;16:1511–1521. https://doi.org/10.1007/s10461-011-0021-0 Robards J, Evandrou M, Falkingham J, Vlachantoni A. Marital status, health and mortality. Maturitas. 2012. https://doi.org/10.1016/j.maturitas.2012.08.007 Shisana O. South African national HIV prevalence, incidence and behaviour survey, 2012 [homepage on the Internet]. HSRC Press; 2014 [cited 2019 Aug 21]. Available from: http://repository.hsrc.ac.za/bitstream/handle/20.500.11910/2490/8162.pdf?sequence=1&isAllowed=y Hadland SE, Milloy M-J, Kerr T, et al. Young age predicts poor antiretroviral adherence and viral load suppression among injection drug users. AIDS Patient Care STDS. 2012;26(5):274–280. https://doi.org/10.1089/apc.2011.0196 Bulage L, Ssewanyana I, Nankabirwa V, et al. Factors associated with virological non-suppression among HIV-positive patients on antiretroviral therapy in Uganda, August 2014-July 2015. BMC Infect Dis. 2017;17(1):326. https://doi.org/10.1186/s12879-017-2428-3 Mujugira A, Celum C, Tappero JW, Ronald A, Mugo N, Baeten JM. Younger age predicts failure to achieve viral suppression and virologic rebound among HIV-1-infected persons in serodiscordant partnerships. AIDS Res Hum Retroviruses. 2016; 32(2):148–154. https://doi.org/10.1089/aid.2015.0296 Akullian AN, Mukose A, Levine GA, Babigumira JB. People living with HIV travel farther to access healthcare: A population-based geographic analysis from rural Uganda. J Int AIDS Soc. 2016;19(1):20171. https://doi.org/10.7448/IAS.19.1.20171 Buor D. Analysing the primacy of distance in the utilization of health services in the Ahafo-Ano South district, Ghana. Int J Health Plann Manage. 2003;18(4):293–311. https://doi.org/10.1002/hpm.729 Schoeps A, Gabrysch S, Niamba L, Sié A, Becher H. The effect of distance to health-care facilities on childhood mortality in rural Burkina Faso. Am J Epidemiol. 2011;173(5):492–498. https://doi.org/10.1093/aje/kwq386 Cluver LD, Hodes RJ, Toska E, et al. ‘HIV is like a tsotsi. ARVs are your guns’: Associations between HIV-disclosure and adherence to antiretroviral treatment among adolescents in South Africa. AIDS. 2015;29 Suppl 1:S57–65. https://doi.org/10.1097/QAD.0000000000000695 Rochat TJ, Mkwanazi N, Bland R. Maternal HIV disclosure to HIV-uninfected children in rural South Africa: A pilot study of a family-based intervention. BMC Public Health. 2015;29 Suppl 1:S57–65. https://doi.org/10.1186/1471-2458-13-147 Wouters E, Van Loon F, Van Rensburg D, Meulemans H. Community support and disclosure of HIV serostatus to family members by public-sector antiretroviral treatment patients in the Free State Province of South Africa. AIDS Patient Care STDS. 2009;23(5):357–364. https://doi.org/10.1089/apc.2008.0201 Kunutsor S, Walley J, Katabira E, et al. Improving clinic attendance and adherence to antiretroviral therapy through a treatment supporter intervention in Uganda: A randomized controlled trial. AIDS Behav. 2011;15(8):1795–1802. https://doi.org/10.1007/s10461-011-9927-9 Nachega JB, Chaisson RE, Goliath R, et al. Randomized controlled trial of trained patient-nominated treatment supporters providing partial directly observed antiretroviral therapy. AIDS. 24(9):1273–1280. https://doi.org/10.1097/QAD.0b013e328339e20e Duwell MM, Knowlton AR, Nachega JB, et al. Patient-nominated, community-based HIV treatment supporters: Patient perspectives, feasibility, challenges, and factors for success in HIV-infected South African adults. AIDS Patient Care STDS. 2013;27(2):96–102. https://doi.org/10.1089/apc.2012.0348 Kanters S, Park JJH, Chan K, et al. Interventions to improve adherence to antiretroviral therapy: A systematic review and network meta-analysis. Lancet HIV. 2017; 4(1):e31–e40. https://doi.org/10.1016/S2352-3018(16)30206-5 Mills EJ, Nachega JB, Bangsberg DR, et al. Adherence to HAART: A systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 2006;3(11):e438. https://doi.org/10.1371/journal.pmed.0030438 Ajose O, Mookerjee S, Mills EJ, Boulle A, Ford N. Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: A systematic review and meta-analysis. AIDS. 2012. https://doi.org/10.1097/QAD.0b013e328351f5b2 Cheng Y, Nickman NA, Jamjian C, et al. Predicting poor adherence to antiretroviral therapy among treatment-naïve veterans infected with human immunodeficiency virus. Medicine. 2018;97(2):e9495. https://doi.org/10.1097/MD.0000000000009495 Petersen ML, Wang Y, Van der Laan MJ, Guzman D, Riley E, Bangsberg DR. Pillbox organizers are associated with improved adherence to HIV antiretroviral therapy and viral suppression: A marginal structural model analysis. Clin Infect Dis. 2007;45(7):908–915. https://doi.org/10.1086/521250 Azia IN, Mukumbang FC, Van Wyk B. Barriers to adherence to antiretroviral treatment in a regional hospital in Vredenburg, Western Cape, South Africa. South Afr J HIV Med. 2016;17(1):476. https://doi.org/10.4102/sajhivmed.v17i1.476 Nozaki I, Dube C, Kakimoto K, Yamada N, Simpungwe JB. Social factors affecting ART adherence in rural settings in Zambia. AIDS Care. 2011;23(7):831–838. https://doi.org/10.1080/09540121.2010.542121 Nassir Azmach N. Adherence to antiretroviral therapy and associated factors among adult ARV users in Arba Minch Hospital, Southern Ethiopia. Cent African J Public Heal. 2017;3(2):19–26. https://doi.org/10.11648/j.cajph.20170302.12 Stawarz K, Rodríguez MD, Cox AL, Blandford A. Understanding the use of contextual cues: Design implications for medication adherence technologies that support remembering. Digit Heal. 2016; 1;2:2055207616678707. https://doi.org/10.1177/2055207616678707 Nkomo G, Mosalo A, Thupayagale-Tshweneagae GB. Adherence to treatment and retention to care of adult patients on antiretroviral therapy. Afr J Nurs Midwifery. 2018;20(1):1–13. https://doi.org/10.25159/2520-5293/1590 Wasti SP, Simkhada P, Randall J, Freeman JV, Van Teijlingen E. Factors influencing adherence to antiretroviral treatment in Nepal: A mixed-methods study. PLoS One. 2012;7(5):e35547. https://doi.org/10.1371/journal.pone.0035547 Fonsah JY, Njamnshi AK, Kouanfack C, et al. Adherence to antiretroviral therapy (ART) in Yaoundé-Cameroon: Association with opportunistic infections, depression, ART regimen and side effects. PLoS One. 2017;12(1):e0170893. https://doi.org/10.1371/journal.pone.0170893 Johnson MO, Dilworth SE, Taylor JM, Neilands TB. Improving coping skills for self-management of treatment side effects can reduce antiretroviral medication nonadherence among people living with HIV. Ann Behav Med. 2011;41(1):83–91. https://doi.org/10.1007/s12160-010-9230-4 Moyo F, Chasela C, Brennan AT, et al. Treatment outcomes of HIV-positive patients on first-line antiretroviral therapy in private versus public HIV clinics in Johannesburg, South Africa. Clin Epidemiol. 2016;8:37–47. https://doi.org/10.2147/CLEP.S93014 Goodman N. The impact of employment on the health status and health care costs of working-age people with disabilities. LEAD Cent Policy Br. 2015. Kilian R, Lauber C, Kalkan R, et al. The relationships between employment, clinical status, and psychiatric hospitalisation in patients with schizophrenia receiving either IPS or a conventional vocational rehabilitation programme. Soc Psychiatry Psychiatr Epidemiol. 2012;47(9):1381–1389. https://doi.org/10.1007/s00127-011-0451-z Barnett W, Patten G, Kerschberger B, et al. Perceived adherence barriers among patients failing second-line antiretroviral therapy in Khayelitsha, South Africa. South Afr J HIV Med. 2013;14(4):170–176. https://doi.org/10.4102/sajhivmed.v14i4.51 Scanlon ML, Vreeman RC. Current strategies for improving access and adherence to antiretroviral therapies in resource-limited settings. HIV/AIDS. 2013;5:1–17. https://doi.org/10.2147/HIV.S28912 Chaiyachati KH, Ogbuoji O, Price M, Suthar AB, Negussie EK, Bärnighausen T. Interventions to improve adherence to antiretroviral therapy: A rapid systematic review. AIDS. 2014; 28:S187–S204. https://doi.org/10.1097/QAD.0000000000000252 Ridgeway K, Dulli LS, Murray KR, et al. Interventions to improve antiretroviral therapy adherence among adolescents in low- and middle-income countries: A systematic review of the literature. PLoS One. 2018;13(1):e0189770. https://doi.org/10.1371/journal.pone.0189770

How to cite this article: Gumede SB, Venter WDF, Lalla-Edward ST. Understanding adherence in virally suppressed and unsuppressed human immunodeficiency virus-positive urban patients on second-line antiretroviral treatment. S Afr J HIV Med. 2020;21(1), a1107. https://doi.org/10.4102/sajhivmed.v21i1.1107